Document is current
Any future updates will be listed below
-
Authors
Solimani, Farzan https://orcid.org/0000-0001-6507-5407
Amagai, Masayuki https://orcid.org/0000-0003-3314-7052
Bollard, Catherine M.
Payne, Aimee S. https://orcid.org/0000-0001-9389-7918
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01-AR082675)
Myasthenia Gravis Foundation of America
MEXT | Japan Society for the Promotion of Science (JP22H04994)
Japan Agency for Medical Research and Development (JP21ek0410058)
Japan Agency for Medical Research and Development (JP21gm1010001)
Japan Agency for Medical Research and Development (JP24ek0109728)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (OT2CA278700)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (UG1HL108945)
- License Information
-
More Information
Article History
Received: 25 July 2025
Accepted: 5 January 2026
First Online: 16 February 2026
Competing interests
: F.S. and M.A. declare no conflicts of interest. C.M.B. is on the Board of Directors of Cabaletta Bio and was the scientific cofounder and Scientific Advisory Board member of Catamaran Bio, has stock in Repertoire Immune Medicines and serves on the data and safety monitoring board of the Swedish Orphan Biovitrum. A.S.P. is co-founder and co-chair of the Scientific Advisory Board of Cabaletta Bio (equity, research support and patent licensing) and has served as a consultant for Sanofi, Bristol Myers Squibb, Janssen, GlycoEra and Avilar Therapeutics.
